The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
A case of HBV-induced liver failure in the REEF-2 phase II trial: Implications for finite treatment strategies in HBV 'cure'
J Hepatol. 2022 Jul;77(1):245-248. doi: 10.1016/j.jhep.2022.03.006.Epub 2022 Mar 28.
1Institute of Liver Studies, King's College Hospital, Denmark Hill, London, UK. Electronic address: kosh.agarwal@nhs.net.
2Institute of Liver Studies, King's College Hospital, Denmark Hill, London, UK.
3Janssen Research & Development, Beerse, Belgium.
4Division of Hepatology, Department of Medicine II, Leipzig University Medical Center, Leipzig, Germany.
Abstract
Nucleoside analogues are the mainstay of treatment for patients with chronic HBV infection but have no direct effect on covalently closed circular DNA. Long-term HBV viral suppression is now routine, but the desirable endpoint of functional cure is rarely achieved. Newer therapies, targeting other aspects of the replicative life cycle of HBV, present opportunities to deliver finite therapy and HBV 'cure'. This is an area of keen focus for the HBV community. We describe a severe case of hepatitis B reactivation, occurring shortly after the withdrawal of a nucleoside analogue within the protocol of a clinical trial (REEF-2). Despite best supportive care and prompt re-introduction of tenofovir, the patient developed subacute liver failure, requiring emergency orthotopic liver transplantation. As we strive to achieve HBV cure, this case highlights the potential risks of finite therapy and highlights the need for improved biomarker-driven strategies and re-evaluation of study protocols.